skip to main content


Shareholder Information

Major Shareholdings

Major shareholder Number of shares Percentage holding
North West Fund (Biomedical) LP 16,186,446 16.35%
RisingStars Growth Fund LP II 11,950,869 12.07%
AXA Framlington Investment Management Limited 8,995,804 9.09%
Seneca Partners Limited 7,243,097  7.32%
Newlands Capital 4,902,315 4.95%
South Yorkshire Investment Fund Limited 3,772,949 3.81%
Partners Investment Company 3,114,089 3.15%
Letzone Limited 3,108,445 3.14%
Sarum Investment SICAV Plc 3,005,053 3.04%

There are  98,991,334  ordinary shares in issue
This page was last updated on 12 February 2019

Latest Investor Presentation

A copy of the latest Investor Presentation is available at this link.

Evgen Investor Symposium 2018: Presentations

Introduction – Dr Stephen Franklin, Evgen Pharma plc
Biotech investment market and Evgen Pharma plc – Vadim Alexandre, Northland Capital
The science behind sulforaphane – Prof Albena Dinkova-Kostova, University of Dundee
The STEM trial in breast cancer – Dr Sacha Howell, Christie Hospital and University of Manchester
The SAS trial in haemorrhagic stroke – Sally Ross,  Evgen Pharma plc

Notice of AGM

A copy of the 2018 AGM notice is available at this link.

Advisers and Registrars

Nominated Adviser and Broker:  finnCap
60 New Broad Street, London, EC2M 1JJ

Solicitors: Pinsent Masons LLP 

Pinsent Masons LLP, 30 Crown Place, London, EC2A 4EN

Auditors: RSM UK Audit LLP
9th Floor, 3 Hardman Street, Manchester, M3 3HF

Reporting Accounts: RSM UK Group LLP

25 Farringdon Street, London, EC4A 4AB

Technical Expert: PharmaVentures Ltd
Triumph House, Parkway Court, Oxford Business Park, Oxford, OX4 2JY

Patent Attorney: HGF Ltd
17-19 Whitworth St West, Manchester, M1 5WG

Financial Public Relations: Buchanan
107 Cheapside, London, EC2V 6DN

Registrars: SLC Registrars
Division of Equiniti David Venus Ltd, 42-50 Hersham Road, Walton on Thames, Surrey, KT12 1RZ